Welcome to the latest episode of 'On the Couch'. This occasional podcast series of chats with fund managers, CEO’s and brokers aims to give you an insight into the investing world.

In this episode I am joined by Paul Rennie the founder and Executive Chairman at Paradigm (PAR).

Paul is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Paul has extensive experience in commercialising Intellectual Property.

• Paradigm Biopharmaceuticals is a late-stage drug development company working with some of the world’s leaders in pharmaceutical product development and approaching science from a completely different angle.
• The immediate commercial focus is the development of injectable pentosan polysulfate sodium (iPPS/PPS, brand name Zilosul®) for the treatment of osteoarthritis (OA). This is a global unmet need and Paradigm has advanced to phase 3 trials in the space. Addressing all aspects of the disease: inflammation, pain and regeneration, PPS has genuine disease modifying potential.
• Pentosan polysulfate sodium (PPS) is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs).

If you enjoyed this podcast, why not sign up for a free trial**? Get access to expert insights and research and become a better investor.

There are also plenty of free podcasts from Marcus Today and the team covering daily updates, chats with fund managers and CEOs of companies that interest us.**